# EDGAR Filing Document

**Accession Number:** 0001789972
**File Stem:** 0000950170-25-085425
**Filing Date:** 2025-6
**Character Count:** 7335
**Document Hash:** c0a181043d3871c21d8943384de0764f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-085425.hdr.sgml**: 20250612

**ACCESSION NUMBER**: 0000950170-25-085425

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20250612

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250612

**DATE AS OF CHANGE**: 20250612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cullinan Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001789972
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 813879991
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39856
- **FILM NUMBER:** 251043054

**BUSINESS ADDRESS:**
- **STREET 1:** ONE MAIN STREET
- **STREET 2:** SUITE 1350
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617-410-4650

**MAIL ADDRESS:**
- **STREET 1:** ONE MAIN STREET
- **STREET 2:** SUITE 1350
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cullinan Oncology, Inc.
- **DATE OF NAME CHANGE:** 20210225

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cullinan Management, Inc.
- **DATE OF NAME CHANGE:** 20210107

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cullinan Oncology, LLC
- **DATE OF NAME CHANGE:** 20191001

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## **FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** June 12, 2025<br>

------

CULLINAN THERAPEUTICS, INC.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-39856 | 81-3879991 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| One Main Street<br>Suite 1350 |  |  |
| Cambridge**,** Massachusetts |  | 02142 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 617 410-4650<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | |
|:---|:---|
| **<br>Title of each class** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share<br> CGEM | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## **Item 5.07 Submission of Matters to a Vote of Security Holders.** 
The Annual Meeting of Stockholders (the "Annual Meeting") of Cullinan Therapeutics, Inc. (the "Company") was held on June 12, 2025. The holders present voted on the four proposals presented at the Annual Meeting as follows.

***Proposal One — Election of Directors*** 

The Company's stockholders elected three Class II directors to the Company's Board of Directors for three-year terms or until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal, by the following votes:

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Nominee** | &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**Votes Withheld** | &nbsp;&nbsp;**Broker Non-Votes** |
| &nbsp;&nbsp;Anthony Rosenberg | &nbsp;&nbsp;47044236 | &nbsp;&nbsp;1926370 | &nbsp;&nbsp;3138175 |
| &nbsp;&nbsp;David P. Ryan, M.D. | &nbsp;&nbsp;47241434 | &nbsp;&nbsp;1729172 | &nbsp;&nbsp;3138175 |
| &nbsp;&nbsp;Mary Thistle | &nbsp;&nbsp;48835369 | &nbsp;&nbsp;135237 | &nbsp;&nbsp;3138175 |

---

***Proposal Two — Ratification of Appointment of Independent Registered Accounting Firm*** 

The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2025 by the following votes:

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**Votes Against** | &nbsp;&nbsp;**Abstentions** | &nbsp;&nbsp;**Broker Non-Votes** |
| &nbsp;&nbsp;51,936,984 | &nbsp;&nbsp;157,477 | &nbsp;&nbsp;14,320 | &nbsp;&nbsp;0 |

---

***Proposal Three — Advisory Vote on Executive Compensation***

The Company's stockholders approved the advisory vote on the compensation of the Company's named executive officers by the following votes:

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**Votes Against** | &nbsp;&nbsp;**Abstentions** | &nbsp;&nbsp;**Broker Non-Votes** |
| &nbsp;&nbsp;46,956,042 | &nbsp;&nbsp;1,999,889 | &nbsp;&nbsp;14,675 | &nbsp;&nbsp;3,138,175 |

---

***Proposal Four — Advisory Vote on the Frequency of Future Executive Compensation Advisory Votes***

The Company's stockholders held an advisory vote on the frequency of future executive compensation advisory votes. The results of the stockholders' vote with respect to the advisory proposal were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Every 1 Year** | &nbsp;&nbsp;**Every 2 Years** | &nbsp;&nbsp;**Every 3 Years** | &nbsp;&nbsp;**Abstentions** | &nbsp;&nbsp;**Broker Non-Votes** |
| &nbsp;&nbsp;48458610 | &nbsp;&nbsp;347 | &nbsp;&nbsp;480946 | &nbsp;&nbsp;30703 | &nbsp;&nbsp;3138175 |

---

After taking into consideration the foregoing voting results and the prior recommendation of the Company's Board of Directors in favor of an annual advisory stockholder vote on the compensation of the Company's named executive officers, the Board of Directors intends to hold future executive compensation advisory votes every year until the next advisory frequency vote. An advisory frequency vote is required to be held at least once every six years.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **CULLINAN THERAPEUTICS, INC.** |
| Date: | June 12, 2025 | By:  | /s/ Mary Kay Fenton |
|  |  |  | Mary Kay Fenton<br>Chief Financial Officer |

---

------